Theralase® Technologies Inc. announced that it has been granted a Clinical Trial Application Amendment ("CTA-A") by Health Canada through receipt of a No Objection Letter ("NOL") for the optimization of the Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study II"). The Study II optimization consists of: 1) Post Study II Monitoring of Response - Patients, who achieved a Complete Response ("CR") or Indeterminate Response ("IR"), demonstrated a duration of that response at 450 days and remained in Study II will be monitored by the Company past 450 days, to help define the long-term duration of the Study II Treatment. 2) Optional Maintenance Study II Treatment -Patients currently receive a mandatory maintenance Study II Treatment at 180 days; however, this has been optimized to allow optional maintenance Study II Treatments, at the discretion of the Principal Investigator ("PI") based on the patient's response.

For patients who have achieved a CR or IR at any point in time and have demonstrated a duration of that CR or IR, no further maintenance Study II Treatments would be administered; however, if the patient recurs at any scheduled assessment visit (i.e.: 90, 180, 270, 360 or 450 days), then that patient would be eligible to receive up to 2 maintenance Study II Treatments at the discretion of the PI to assist the patient in achieving a CR. 3) Central Pathology Laboratory Review - Use of a central pathology laboratory to validate local pathology laboratory results. Note: CR is defined as: Negative cystoscopy and negative (including atypical) urine cytology, Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology and Negative cystoscopy with malignant urine cytology, if urothelial cancer is suspected in the upper tract or prostatic urethra and rand adder biopsies are negative.

Note: IR is defined as: Negative cystoscopy and positive urine cytology, without confirmatory negative bladdercancer biopsies.